Clinical Trials in Sakura, Japan
5 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 2
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Heart Failure
Pfizer620 enrolled125 locationsNCT06991257
Recruiting
Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
Ulcerative Colitis (UC)
Bristol-Myers Squibb150 enrolled17 locationsNCT07271069
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC220 enrolled104 locationsNCT06919965
Recruiting
Phase 1Phase 2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Takeda207 enrolled140 locationsNCT06254950
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled497 locationsNCT06430801
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled274 locationsNCT06925737
Recruiting
Phase 2Phase 3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Janssen Research & Development, LLC1,092 enrolled324 locationsNCT07196722
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled281 locationsNCT06136624
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled320 locationsNCT06136650
Recruiting
Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Inflammatory Bowel DiseasesCrohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)385 enrolled159 locationsNCT06226883
Recruiting
Phase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Ulcerative Colitis
Eli Lilly and Company252 enrolled147 locationsNCT07186101
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
AbbVie200 enrolled27 locationsNCT07136116
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Crohn's Disease
Sanofi260 enrolled134 locationsNCT06637631
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled279 locationsNCT06764485
Recruiting
Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC663 enrolled81 locationsNCT07164443